$1.4B deal: Ozempic manufacturer to acquire Canadian developer of new obesity drug
At the heart of Novo Nordisk’s acquisition of Montreal-based Inversago Pharma is an oral agonist designed to block the receptor protein CB1, which plays an important role in metabolism and appetite regulation.